Healthcare
Diaceutics PLC(DIUXF)
Live Price
Offline$2.00
+0.00% today
1Y Change
+46.28%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $150.00M
- Revenue Growth
- +35.7%
- EPS Growth
- +2.4%
- Dividend Yield
- 0.0%
Coverage: 255 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Diaceutics PLC (DIUXF) is a Healthcare stock with a market cap of $150.00M and listed on OTC. The stock last traded around $2.00 and up 46.3% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +35.7%, EPS growth of +2.4%, a dividend yield of 0.0%. What stands out right now is revenue +35.7%, EPS +2.4%, free cash flow -12.3% with operating margin -6.4% and ROIC -5.1%. Valuation sits in the middle of the pack at price/sales 4.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DIUXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+35.7% vs +7.6% peer median
Operating Margin
Below sector median
-6.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Jan 15, 2026 with an EPS surprise of -30.6% and a revenue surprise of -5.4%.
The operating story is still moving forward
Revenue is running at +35.7% and EPS at +2.4%, with operating margin around -6.4%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 15, 2026 | -30.6% | +0.0% | +0.0% | +0.0% |
2025 Sep 23, 2025 | -3.3% | +0.0% | +0.0% | +0.0% |
2025 May 13, 2025 | -50.9% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
DIUXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DIUXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DIUXF Max Drawdown
-2.44%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DIUXF and SPY.
Company Overview
Diaceutics PLC
Other OTC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
- Leadership
- Ryan Keeling
- IPO Date
- May 29, 2020
- Employees
- 184
- Street Address
- Building Two
- Mailing
- Belfast, BT9 6GW
- Region
- Belfast, GB
- Reporting Currency
- USD
- Investor Line
- +44 28 9042 8133
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 50.6
- Price/Sales
- 4.2
- Price/Book
- 2.0
Growth
- Revenue
- +35.7%
- EPS
- +2.4%
- Free Cash Flow
- -12.3%
Profitability
- Gross Margin
- 86.1%
- Operating Margin
- -6.4%
- Net Margin
- -4.4%
- ROE
- -3.9%
- ROIC
- -5.1%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 3.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.